• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Alterations in cardiac energy metabolism contribute to the severity of heart failure. However,
the energy metabolic changes that occur in heart failure are complex and are dependent not …

Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Background The inflammatory response occurring in acute myocardial infarction (AMI) has
been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Arterial hypertension is the most important contributor to the global burden of disease;
however, disease control remains poor. Although the diagnosis of hypertension is still based …

Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …

Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …